Skip to main content
Journal cover image

High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes.

Publication ,  Journal Article
Stuart, MJ; Peters, WP; Broadwater, G; Hussein, A; Ross, M; Marks, LB; Folz, RJ; Long, GD; Rizzieri, D; Chao, NJ; Vredenburgh, JJ
Published in: Biol Blood Marrow Transplant
2002

Despite modern chemotherapy, advanced breast cancer remains a significant cause of cancer morbidity and mortality in women. Patients with disease involvement of multiple lymph nodes represent a subgroup with a high risk of relapse. In particular, 50% of patients with 4 to 9 axillary lymph nodes involved will relapse after standard chemotherapy. In an effort to improve the survival of patients with 4 to 9 involved nodes, we performed a phase II study in which 61 patients with surgically diagnosed stage II or III breast cancer and 4 to 9 positive lymph nodes received 3 cycles of doxorubicin and 5-fluorouracil followed by high-dose chemotherapy consisting of cisplatin, cyclophosphamide, and carmustine and infusion of autologous hematopoietic progenitor cells. All patients received posttransplantation localized radiotherapy unless contraindicated, and all patients with hormone receptor-positive disease received tamoxifen. After a median patient follow-up of 6.7 years (range, 4.6-8.6 years), the 5-year overall survival rate was 79% (95% CI, 69%-90%), with relapse-free survival of 73% (95% CI, 62%-85%). Treatment-related mortality was 3%. Interstitial pneumonitis occurred in 69% of patients but did not contribute to mortality. Our study presents long-term favorable results regarding the use of consolidative HDC with autologous hematopoietic support in previously untreated patients with high-risk primary breast cancer.

Duke Scholars

Published In

Biol Blood Marrow Transplant

DOI

ISSN

1083-8791

Publication Date

2002

Volume

8

Issue

12

Start / End Page

666 / 673

Location

United States

Related Subject Headings

  • Transplantation, Autologous
  • Survival Analysis
  • Stem Cell Transplantation
  • Regression Analysis
  • Recombinant Proteins
  • Patient Selection
  • Multivariate Analysis
  • Middle Aged
  • Lymphatic Metastasis
  • Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Stuart, M. J., Peters, W. P., Broadwater, G., Hussein, A., Ross, M., Marks, L. B., … Vredenburgh, J. J. (2002). High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes. Biol Blood Marrow Transplant, 8(12), 666–673. https://doi.org/10.1053/bbmt.2002.v8.abbmt080666
Stuart, Monic J., William P. Peters, Gloria Broadwater, Atif Hussein, Maureen Ross, Lawrence B. Marks, Rodney J. Folz, et al. “High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes.Biol Blood Marrow Transplant 8, no. 12 (2002): 666–73. https://doi.org/10.1053/bbmt.2002.v8.abbmt080666.
Stuart MJ, Peters WP, Broadwater G, Hussein A, Ross M, Marks LB, et al. High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes. Biol Blood Marrow Transplant. 2002;8(12):666–73.
Stuart, Monic J., et al. “High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes.Biol Blood Marrow Transplant, vol. 8, no. 12, 2002, pp. 666–73. Pubmed, doi:10.1053/bbmt.2002.v8.abbmt080666.
Stuart MJ, Peters WP, Broadwater G, Hussein A, Ross M, Marks LB, Folz RJ, Long GD, Rizzieri D, Chao NJ, Vredenburgh JJ. High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes. Biol Blood Marrow Transplant. 2002;8(12):666–673.
Journal cover image

Published In

Biol Blood Marrow Transplant

DOI

ISSN

1083-8791

Publication Date

2002

Volume

8

Issue

12

Start / End Page

666 / 673

Location

United States

Related Subject Headings

  • Transplantation, Autologous
  • Survival Analysis
  • Stem Cell Transplantation
  • Regression Analysis
  • Recombinant Proteins
  • Patient Selection
  • Multivariate Analysis
  • Middle Aged
  • Lymphatic Metastasis
  • Immunology